XML 36 R21.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stock-Based Compensation Plans
12 Months Ended
Dec. 31, 2015
Stock-Based Compensation Plans [Abstract]  
Stock-Based Compensation Plans
12.Stock-Based Compensation Plans

Our stock-based compensation program is a broad-based program designed to attract and retain employees while also aligning employees’ interests with the interests of our shareholders. In addition, members of our Board of Directors participate in our stock-based compensation program in connection with their service on our board. During 2015, we had three active stock-based compensation plans. As of December 31, 2015, we have only one active stock-based compensation plan, the 2006 Omnibus Incentive Plan. During 2015, the 2004 Omnibus Stock Option Plan and the 2004 Independent Directors Plan terminated as all outstanding options under the plans were exercised during the year.
 
We account for our stock-based compensation plans in accordance with the provisions of FASB ASC 718, Stock Compensation, which requires that a company measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The service period is the period of time that the grantee must provide services to us before the stock-based compensation is fully vested.
 
Under the 2006 Omnibus Incentive Plan, which terminates in May 2016, we are authorized to issue, among other things, stock options and shares of restricted and performance based stock to eligible employees and directors of up to 1,900,000 shares of common stock. Stock options forfeited under the previous stock option plans and equity awards under the incentive plan are eligible to be granted again under the 2006 Omnibus Incentive Plan with respect to stock options and equity awards so forfeited.
 
Stock-based compensation expense under our existing plans was $5.0 million ($3.2 million, net of tax) or $0.14 per basic and diluted share, $4.3 million ($2.8 million, net of tax) or $0.12 per basic and diluted share, and $3.2 million ($2 million, net of tax) or $0.09 per basic and diluted share for the years ended December 31, 2015, 2014 and 2013, respectively.

Stock Option Grants
 
The following is a summary of the changes in outstanding stock options for the years ended December 31, 2015 and 2014:
 
   
Shares
  
Weighted
Average
Exercise
Price
  
Weighted Average
Remaining
Contractual
Term (Years)
 
          
Outstanding at December 31, 2013
  
16,875
  
$
12.14
   
1.0
 
Expired
  
   
   
 
Exercised
  
(7,000
)
  
13.76
   
 
Forfeited, other
  
   
   
 
Outstanding at December 31, 2014
  
9,875
   
10.99
   
0.4
 
Expired
  
   
   
 
Exercised
  
(9,875
)
  
10.99
   
 
Forfeited, other
  
   
   
 
Outstanding at December 31, 2015
  
  
$
   
 
             
Options exercisable at December 31, 2015
  
  
$
   
 
 

 
The total intrinsic value of options exercised for the years ended December 31, 2015 and 2014 was $0.3 million and $0.2 million, respectively. There were no stock options granted in 2015.

Restricted Stock and Performance Share Grants

As part of the 2006 Omnibus Incentive Plan, we currently grant shares of restricted stock to eligible employees and our independent directors and performance-based stock to eligible employees. Selected executives and other key personnel are granted performance awards whose vesting is contingent upon meeting various performance measures with a retention feature. Performance-based shares are subject to a three year measuring period and the achievement of performance targets and, depending upon the achievement of such performance targets, they may become vested on the third anniversary of the date of grant. Each period we evaluate the probability of achieving the applicable targets and we adjust our accrual accordingly. Restricted shares granted to employees become fully vested upon the third anniversary of the date of grant; and for selected key executives certain additional restricted share grants vest 25% upon the attainment of age 60, 25% upon the attainment of age 63 and become fully vested upon the attainment of age 65. Restricted shares granted to directors become fully vested upon the first anniversary of the date of grant. Commencing with the 2015 grants, restricted and performance shares issued to certain key executives and directors are subject to a one or two year holding period upon the lapse of the three year vesting period.
 
Prior to the time a restricted share becomes fully vested or a performance share is issued, the awardees cannot transfer, pledge, hypothecate or encumber such shares. Prior to the time a restricted share is fully vested, the awardees have all other rights of a stockholder, including the right to vote (but not receive dividends during the vesting period). Prior to the time a performance share is issued, the awardees shall have no rights as a stockholder. All shares and rights are subject to forfeiture if certain employment conditions are not met.
 
Under the 2006 Omnibus Incentive Plan, 1,900,000 shares are authorized to be issued. At December 31, 2015, under the plan, there were an aggregate of (a) 1,618,380 shares of restricted and performance-based stock grants issued, net of forfeitures, and (b) 281,620 shares of common stock available for future grants. For the year ended December 31, 2015, 211,950 restricted and performance-based shares were granted (164,450 restricted shares and 47,500 performance-based shares), and for the year ended December 31, 2014, 256,443 restricted and performance-based shares were granted (210,193 restricted shares and 46,250 performance-based shares).
 
In determining the grant date fair value, the stock price on the date of grant, as quoted on the New York Stock Exchange, was reduced by the present value of dividends expected to be paid on the shares issued and outstanding during the requisite service period, discounted at a risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury rates at the date of grant with maturity dates approximately equal to the restriction or vesting period at the grant date. In addition, a further discount for the lack of marketability reduced the fair value of grants issued to certain key executives and directors subject to the one or two year post vesting holding period. Assumptions used in calculating the discount for the lack of marketability include an estimate of stock volatility, risk-free interest rate, and a dividend yield.
 
The fair value of the shares at the date of grant is amortized to expense ratably over the vesting period. Forfeitures on restricted stock grants are estimated at 5% for employees and 0% for executives and directors, respectively, based on evaluation of historical and expected future turnover.
 
As related to restricted and performance stock shares, we recorded compensation expense of $5.0 million ($3.2 million, net of tax), $4.3 million ($2.8 million, net of tax) and $3.2 million ($2 million, net of tax), for the years ended December 31, 2015, 2014 and 2013, respectively. The unamortized compensation expense related to our restricted and performance-based shares was $12.7 million and $11.8 million at December 31, 2015 and 2014, respectively and is expected to be recognized over a weighted average period of 5.8 years and 0.3 years for employees and directors, respectively, as of December 31, 2015 and over a weighted average period of 5.1 years and 0.3 years for employees and directors, respectively, as of December 31, 2014.
 
Our restricted and performance-based share activity was as follows for the years ended December 31, 2015 and 2014:
 
  
Shares
  
Weighted Average
Grant Date Fair
Value per Share
 
Balance at December 31, 2013
  
630,600
  
$
19.47
 
Granted
  
256,443
   
32.22
 
Vested
  
(132,325
)
  
15.50
 
Forfeited
  
(5,700
)
  
18.77
 
Balance at December 31, 2014
  
749,018
   
24.62
 
Granted
  
211,950
   
31.79
 
Vested
  
(192,768
)
  
22.13
 
Forfeited
  
(9,650
)
  
29.30
 
Balance at December 31, 2015
  
758,550
  
$
27.19
 

The weighted-average grant date fair value of restricted and performance-based shares outstanding as of December 31, 2015, 2014 and 2013 was $20.6 million (or $27.19 per share), $18.4 million (or $24.62 share), and $12.3 million (or $19.47 per share), respectively.